Blinatumomab
Description
Blinatumomab is a bi-specific T-cell engager antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker. CD3 is an antigen expressed on the surface of T-cells, while CD19 is an antigen expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it bringing T-cells and tumor cells expressing CD19 together and induces an immune response that leads to T-cell activation and proliferation. Together, Blinatumomab promotes the lysis of CD19+ tumor cells.
Product name | Blinatumomab Biosimilar |
Species | Homo sapiens |
Expression system | CHO-K1 |
Buffer | PBS, pH 7.4 |
Delivery condition | Dry ice (-80°C) |
Delivery Time | 1 week if in stock; 4 weeks if production needed |
Storage condition | Store at -80°C |
Brand | BioMetas |
Applications | ELISA, assay, in vivo |
Aliases/Synonyms | BLINCYTO®, AMG103, BITE MT-103, bscCD19xCD3, MEDI-538, MT103 |
Reference | |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Isotype | Tandem scFv |
Clonality | Monoclonal Antibody |
Size | 1mg, 5mg, 10mg, 50mg, 100mg |
Brand | BioMetas |
Product type | Biosimilar |
Clonality | Monoclonal Antibody |
Expression system | CHOK1 |
Applications | Elisa, assay, in vivo |
Contact Us for a Quote!
Data Gallery
Fig. 1.) 4-20% SDS-PAGE analysis
Recombinant protein was visualized by Coomassie Brilliant Blue R250 staining.
Fig. 2.) SEC-HPLC analysis
Column: Superdex 200 Increase 5/150 GL
Running buffer: 2xPBS, pH 7.4
